Levotofisopam

DB19073InvestigationalSmall molecule

Levotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).

Formula / weight: C₂₂H₂₆N₂O₄ · 382.46 g/mol (avg)
Also known as: (-)-(5s)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine · (s)-tofisopam · 5h-2,3-benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl, (5s)-

Resolves to

Compound

UNII11ZYL7QK34CAS82059-51-6ChEMBLCHEMBL2107351

Structure

InChIKeyRUJBDQSFYCKFAA-OAHLLOKOSA-NSMILESCC[C@H]1C2=CC(OC)=C(OC)C=C2C(=NN=C1C)C1=CC=C(OC)C(OC)=C1

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Levotofisopam, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account